News

FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease

TEASE: a phase 2 clinical trial assessing the tolerability and effects of oral once-a-day ALK-001 on Stargardt disease

Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies?

The Rate of Vitamin A Dimerization in Lipofuscinogenesis, Fundus Autofluorescence, Retinal Senescence and Degeneration

Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization

Morphological and physiological retinal degeneration induced by intravenous delivery of vitamin A dimers in rabbits

Vitamin A dimers trigger the protracted death of retinal pigment epithelium cells

The retina rapidly incorporates ingested C20-D₃-vitamin A in a swine model